Introduction for Baricinix 4 mg (Baricitinib) :

Each film-coated Baricitinix 4 mg tablet contains Baricitinib INN 4 mg. Baricinix  is manufactured by Beacon Pharma Ltd. in Bangladesh.Baricinix which generic name is Baricinix is a medicine that is prescribed  to treat rheumatoid arthritis, an inflammatory disease that causes the body to attack its own joints and organs. Baricinix  4 reduces joint discomfort, soreness, edema, and stiffness.
Baricitinib 4 is to be taken orally once daily, with or without food. Baricinix  4 mg appears as a symbol of hope, delivering not only relief but a paradigm breakthrough in the fight against RA. This thorough investigation intends to shed light on the complexities of Baricinix  4 Mg, its mechanism, applications, production excellence, and the joint efforts of its producer and supplier to make it available globally.

Indications:

Baricinix is used to treat adult patients with moderate to severe active rheumatoid arthritis who have not responded to one or more tumor necrosis factor (TNF) antagonist treatments.Baricinix should not be used in combination with other JAK inhibitors, biologic DMARDs, or powerful immunosuppressants such as azathioprine and cyclosporine. But for serious infections avoid using Baricinix in patients who have an active, serious illness, especially localized infections.Baricinix should not be administered to patients with active TB.Baricinix 4 mg to be dispensed only by the prescription of a registered physician.

Therapeutic/Drug Class:

Immunosuppressant.

Pharmacolog:

Baricinix 4 is a selective and reversible inhibitor of the Janus kinases JAK1 and JAK2. Janus kinases (JAKs) are enzymes that carry intracellular signals from cell surface receptors for a variety of cytokines and growth factors involved in haematopoiesis, inflammation, and immunity. JAKs phosphorylate and activate signal transducers and activators of transcription (STATs) in the intracellular signalling pathway, causing gene expression to increase within the cell. Baricinix 4 modulates these signaling pathways by partially decreasing JAK1 and JAK2 enzymatic activity, reducing STAT phosphorylation and activation.

Dosage and Administration:

Baricinix  4 mg  is advised for adults at a dose of 2 mg once per day. Baricinix  4 mg can be used alone or in combination with methotrexate or other disease-modifying antirheumatic medications (DMARDs). Baricinix  4 mg can be administered orally, with or without food.
Pediatric Use: Baricinix  4 mg’s safety and efficacy in pediatric patients have not been established.
Geriatric Use: Because older people are more prone to have impaired renal function, dose selection of Baricinix  4 mg should be carefully considered.
Hepatic impairment: Patients with mild or moderate hepatic impairment do not require a dosage change.
Renal impairment: Baricinix  4 mg is not indicated for patients with an estimated GFR of less than 60 mL/min/1.73 m2.

Interaction:

Co-administration of Baricinix  4 mg  with powerful OAT3 inhibitors, such as probenecid, leads to increased exposure.

Other JAK Inhibitors or Biologic DMARDs: Baricinix  4 mg  has not been tested in combination with other JAK inhibitors or biologic DMARDS.

Side Effects:
The most prevalent adverse drug reactions (ADRs) of Baricinix 4 reported in 2% of patients treated with Baricinix monotherapy or in combination with traditional synthetic DMARDs were elevated LDL cholesterol (33.6%), upper respiratory tract infections (14.7%), and nausea (2.8%).

Contraindications:
Anemia: The individuals with hemoglobin levels below 8 g/dL, Baricinix  4 should not be initiated or discontinued.
Lymphopenia: Baricinix  4 should not be initiated or stopped in patients with an Absolute Lymphocyte Count of fewer than 500 cells/mm3.
Neutropenia: The individuals with an Absolute Neutrophil Count of less than 1000 cells/mm3, Baricinix  4 should not be started or stopped.

Overdose:
To avoid overdosing, take Baricinix  4 mg as soon as you remember, but skip the missed dose if it is close to your next scheduled administration. Don’t double your doses and hope for the best.

Pregnancy & Lactation:
Studies suggest that Baricinix  4 may harm a fetus when administered to a pregnant woman. Pregnant women should be informed about the potential harm to the fetus. Baricinix ‘s presence in human milk, effects on milk supply, and impact on breastfed infants are unknown. So breastfeeding during Baricinix  4  treatment and for 3 weeks following the last dosage of Baricinix  4 is not recommended due to the risk of major adverse effects in breastfed infants.

Storage Conditions:

Baricinix  150 mg should be kept between 25°C and 30°C at room temperature. When a medication is no longer needed or has expired, dispose of it safely. Protect Baricinix  150 mg from sunlight and humidity. Keep Baricinix  150 mg and all medicines out of the reach of children.

See more Oncology medicine visit our Shop